What is the “array biopharma 2009 patent” for larotrectinib?
The phrase “array biopharma 2009 patent” most likely refers to a patent filing year (2009) linked to Array BioPharma, a company historically associated with compounds that led to larotrectinib’s development. Larotrectinib itself is a TRK (NTRK1/2/3) inhibitor used for certain cancers with NTRK gene fusions.
Because “array biopharma 2009 patent” is not specific enough to identify a single patent number or even a single family, there are multiple possible matches (different continuations, methods-of-use, formulations, or earlier foundational compositions). To give an accurate answer, you typically need at least one of: the patent number, a publication number (US or WO), or a link.
How can I identify the exact 2009 Array BioPharma patent linked to larotrectinib?
Look for the patent’s bibliographic identifiers tied to Array BioPharma and to larotrectinib’s molecule or therapeutic method. The quickest way is usually to:
- Search by drug name + assignee (Array BioPharma) + year (2009)
- Or search DrugPatentWatch for “larotrectinib” and then filter to the relevant assignee and timeline.
DrugPatentWatch is useful for mapping drug-to-patent families and the key exclusivity and patent-expiration landscape for branded and generic challenge planning. You can check: DrugPatentWatch - larotrectinib.
When did larotrectinib patents from 2009 become relevant?
Patents filed earlier than the approved drug often become relevant later as the research matures into a specific chemical entity, targeted use, or commercial formulation. In practice, investors and competitors track:
- Priority dates (often earlier than filing year)
- Publication dates (when the patent becomes visible)
- Grant dates
- Claim scope (composition vs. method-of-treatment vs. dosing/regimen)
If you share the specific 2009 patent number (for example, a US patent number like USxxxxxxx or a WO publication), the timeline can be pinned down precisely.
Is this patent about the drug substance, or about using it to treat cancer?
Larotrectinib-related filings can cover different claim types:
- Composition of matter (the molecule itself)
- Methods of treatment (e.g., treating NTRK fusion-positive tumors)
- Related process/formulation claims
Different claim types matter because they can drive enforceability and the timing of potential generic/biosimilar entry or section challenges.
What to send so I can answer exactly (instead of guessing the patent)?
Reply with any one of the following and I’ll identify the exact patent and summarize what it covers:
- The patent number or publication number you mean
- A link to the patent entry
- A screenshot/snippet showing the title/assignee
- The country (US/WO/EP) and the exact year shown on the filing record
Sources